Banerjee Subhashis sold $12K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 1,100 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 on 2026-09-03.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Sep 4, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine sale with limited market impact.

02

Market read

Minor insider sale; unlikely to affect price or sector sentiment.

03

What to watch

The insider still holds 140,947 shares, indicating confidence despite the sale.

Relevance 3/10Novelty 2/10Timing: post filing 2026-09-04

Background

Form 4 filing from SEC EDGAR reporting an insider transaction.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Chief Medical Officer Banerjee Subhashis sold 1,100 shares for $12,271 on 2026-09-03 via an open‑market transaction.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

The sale size ($12k) is tiny relative to market cap and insider holdings; no indication of distress.

Market effects

None; biotech sector not affected by a micro insider sale.

None; only a US‑listed micro‑cap is involved.

None

Counterpoint

Even small insider sales can signal concerns; monitor subsequent filings for pattern.

Key entities

  • Artiva Biotherapeutics, Inc.

    US‑listed biotech (NASDAQ: ARTV).

  • Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.